Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DCC
REST API REST API
Homo sapiens
DCC is differentially expressed in 153 experiments: 99 organism parts: lung, ovary, ... (97 more);, 115 disease states: normal, myeloma, ... (113 more);, 41 cell types 173 cell lines 9 compound treatments and 67 other conditions.
Synonyms IGDCC1
Orthologs DCC (2 of 2) (Danio rerio)   Dcc (Mus musculus)   Dcc (Rattus norvegicus)   fra (Drosophila melanogaster)   DCC (1 of 2) (Danio rerio)   ENSCING00000009804 (Ciona intestinalis)   DCC (Xenopus laevis)   DCC (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Neogenin_C, Ig_I-set, Fibronectin_type3
Gene Ontology Term cytosol, plasma membrane, protein binding, apoptosis, membrane raft, identical protein binding, induction of apoptosis, netrin receptor activity, axon guidance, multicellular organismal development, transcription coactivator activity, receptor activity, axonogenesis, integral to membrane, regulation of apoptosis, positive regulation of neuron projection development, negative regulation of neuron projection development, positive regulation of ERK1 and ERK2 cascade, growth cone membrane, negative regulation of collateral sprouting, response to amphetamine, negative regulation of dendrite development, transmembrane signaling receptor activity
Gene-Disease Assocation MIRROR MOVEMENTS, CONGENITAL
UniProt Accession P43146, E7EQM8
Search EB-eye ENSG00000187323
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-MTAB-24, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-1309, E-GEOD-1880, E-GEOD-22152, E-GEOD-22639, ... (24 experiments)

Factor Value U/D Experiments
HL-60
2
E-MTAB-37, E-GEOD-24147
GM02783
1
E-TABM-321
MCIXC
1
E-MTAB-37
NCIH1563
1
E-MTAB-37
NCIH1355
1
E-MTAB-37
ARH77
1
E-MTAB-37
167 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-25, E-GEOD-21668, ... (21 experiments)

Factor Value U/D Experiments
testis - germ cell
1
E-AFMX-5
leydig cell
1
E-MTAB-25
CD56+ NK cells
1
1
E-AFMX-5
BDCA4+ dentritic cells
1
E-AFMX-5
cardiac myocyte
1
E-AFMX-5
immortalised T lymphocytes
1
E-GEOD-13909
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-GEOD-20602, E-GEOD-9692, ... (32 experiments)

Factor Value U/D Experiments
normal
5
8
E-GEOD-3167, E-TABM-702, E-GEOD-10927, E-GEOD-6338, E-GEOD-12662, ... (13 experiments)
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
myeloma
1
2
E-MTAB-37, E-MTAB-372, E-MTAB-62
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
1
E-GEOD-3167
109 more value(s).


Compound treatment

studied in E-MEXP-1601, E-MEXP-1269, E-GEOD-3284, E-GEOD-6907, E-GEOD-412, ... (7 experiments)

Factor Value U/D Experiments
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
glutamine
1
1
E-MEXP-1335
control
31
1
E-GEOD-3284
none
1
1
E-GEOD-412, E-MEXP-1601
hydrogen peroxide
2
1
E-GEOD-5339
placebo
1
E-MEXP-1335
3 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
46
2
1
E-GEOD-3494
38
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-4006

Genotype
studied in E-GEOD-1923, E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-TABM-868, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-440

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-GEOD-19330, E-TABM-666, E-GEOD-19519, E-TABM-15, ... (19 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-3697

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4271

Tumor size
studied in E-GEOD-8167

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM